Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ancestry-Specific Structural Variation at 17q21.31 Reveals a Novel H1 Sub-Haplotype and Functional Effects on Tau Biology

ABSTRACT: This study investigates how structural variation at the 17q21.31 locus influences MAPT transcript diversity across ancestries and cellular contexts. The locus contains the H1 and H2 haplotypes, which differ by a large inversion and are associated with distinct risks for neurodegenerative disease. To characterize ancestry- and haplotype-specific tau isoform expression, targeted long-read Iso-Seq was performed on human postmortem brain tissue samples from caudate and Middle Frontal Gyrus, as well as induced pluripotent stem cell–derived neurons and astrocytes. Samples represented multiple haplotype groups and ancestries, including a newly identified African-enriched H1 sub-haplotype (H1_A). Full-length transcript sequencing was used to identify known and novel MAPT isoforms, quantify relative isoform usage, and compare splicing patterns across tissues and cell types. These data provide a resource for understanding how population-specific genomic structure at 17q21.31 may shape tau biology and neurodegenerative disease susceptibility.

ORGANISM(S): Homo sapiens

PROVIDER: GSE328854 | GEO | 2026/05/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

17q21.31 locus regulates Parkinson’s disease relevant pathways through KANSL1 activity

Project description:An inversion polymorphism at the 17q21.31 locus defines the H1 and H2 haplotypes, with the former linked to multiple neurodegenerative disorders, including an increased risk of Parkinson’s disease (PD). Although the high linkage disequilibrium at this locus has made it difficult to decipher which gene(s) drive the PD association, there is increasing evidence to support the role of KANSL1 as a risk gene. KANSL1 has been shown to regulate the expression of some PD-associated genes and pathways, likely as part of the histone acetylating non-specific lethal (NSL) complex. Here for the first time, we studied the global effects of 17q21.31 haplotype variation using bulk and single-nuclear RNA-sequencing data from control and PD patient brain. We first analysed differential gene expression across haplotype groups, and then assessed the contribution of KANSL1 by comparing with the results of an siRNA knockdown in neuronal and glial human cell lines. We demonstrated that the PD risk-associated H1 haplotype downregulates autophagy, lysosomal and mitochondrial processes, all of which have already been implicated in PD aetiology. Furthermore, these effects were apparent in both neuronal and glial cell types, and in the case of the latter, appear to be associated with the modulation of innate and adaptive immune responses. Thus, we identify important links between NSL complex activity and PD pathophysiology that can be leveraged for novel therapeutic interventions.

2025-03-17 | GSE283747 | GEO

Custom Agilent array-CGH of somatic cell hybrids targeted to 17q21.31 deletion syndrome locus

Project description:This is array CGH data of recurrent 17q21.31 deletions used to delineate breakpoints within segmental duplications in a study by Itsara et al. Somatic cell hybrids were generated from three parent-child trios probands with 17q21.31 deletions and three 17q21.31 probands for which no parental DNA was available that isolated individual chromosome 17 homologues. In parents, this isolated the H2 from the H1 haplotypes in distinct cell lines, and in probands, isolated the deletion-bearing chromosomes from the unaffected chromosome 17. In parent-child trios, the deletion-bearing chromosomes were hybridized against the progenitor parental chromosome. In probands with no parental DNA, the deletion-bearing chromosomes were hybridized against an H2 chromosome. 6 experimental hybes of deletion-bearing proband vs H2 chromosome reference. 3 control hybes of H1 vs H2 haplotype, H2 vs H2 haplotype (different individuals), and H1 vs deletion-bearing H2 haplotype.

2012-06-01 | E-GEOD-34867 | biostudies-arrayexpress

An Epigenetic Signature in Peripheral Blood Associated with Neurodegenerative Tauopathy and the Risk-Associated Haplotype on 17q21.31

2014-06-01 | GSE53740 | GEO

An Epigenetic Signature in Peripheral Blood Associated with Neurodegenerative Tauopathy and the Risk-Associated Haplotype on 17q21.31

Project description:Progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) are two neurodegenerative diseases linked, at the pathologic and genetic level, to the macrutubule associated protein tau. We identified and replicated a dose-dependent effect of the risk-associated H1 haplotype on methylation levels within the region in independent datasets in blood and brain. These data reveal that the H1 haplotype increases risk for tauopathy via differential methylation, indicating a mediating role for methylation in dementia pathophysiology. We studied epigenetic changes (DNA methylation levels) in peripheral blood from patients with PSP, FTD, and unaffected controls. Analysis of genome-wide methylation patterns revealed significant differentially methylated probes in patients versus unaffected controls.

2014-06-01 | E-GEOD-53740 | biostudies-arrayexpress

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response

Project description:Tau (MAPT) is a microtubule-associated protein causing frequent neurodegenerative diseases or inherited frontotemporal lobar degenerations. Emerging evidence for non-canonical functions of Tau in DNA protection and P53 regulation suggests its involvement in cancer. Indeed, Tau expression correlates with cancer-specific survival or response to microtubule therapeutics. These data may imply common molecular pathways involved in the pathogenesis of neurodegenerative disorders and cancer. To bring new evidence that Tau represents a key protein in cancer, we present an in silico pan-cancer analysis of MAPT transcriptomic profile in over 11000 clinical samples and over 1300 pre-clinical samples provided by the TCGA and the DEPMAP datasets respectively. We completed this analysis by exploring a possible interplay of MAPT with wild-type or mutated P53. Then, we calculated the impact of MAPT expression on clinical outcome and drug response. Overall, the results support a relevant role of the MAPT gene in several cancer types, although the contribution of Tau to cancer appears to very much depend on the cellular context.

2022-11-27 | E-MTAB-8166 | biostudies-arrayexpress

Custom Agilent array-CGH of somatic cell hybrids targeted to 17q21.31 deletion syndrome locus

2012-06-02 | GSE34867 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [ATAC-seq]

Project description:Tau is encoded by MAPT and abnormal aggregates of tau are a hallmark of a group of neurodegenerative diseases called tauopathies. MAPT is lowly expressed in neural progenitor cells (NPCs), but it is more highly expressed in oligodendrocytes, astrocytes, and neurons that derive from NPCs. This expression switch at differentiation suggests that MAPT expression is controlled by transcription factors and cis-regulatory elements specific to these differentiated cell types, including neurons.

2023-04-12 | GSE228117 | GEO

MAPT expression is regulated by long-range interactions with cis-regulatory elements [ChIP-seq]

2023-04-12 | GSE228116 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [RNA-seq]

2023-04-12 | GSE228115 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [scMultiomics]

2023-04-12 | GSE228120 | GEO